Intra-tumoral T Cells in Pediatric Brain Tumors Display Clonal Expansion and Effector Properties
Overview
Authors
Affiliations
Brain tumors in children are a devastating disease in a high proportion of patients. Owing to inconsistent results in clinical trials in unstratified patients, the role of immunotherapy remains unclear. We performed an in-depth survey of the single-cell transcriptomes and clonal relationship of intra-tumoral T cells from children with brain tumors. Our results demonstrate that a large fraction of T cells in the tumor tissue are clonally expanded with the potential to recognize tumor antigens. Such clonally expanded T cells display enrichment of transcripts linked to effector function, tissue residency, immune checkpoints and signatures of neoantigen-specific T cells and immunotherapy response. We identify neoantigens in pediatric brain tumors and show that neoantigen-specific T cell gene signatures are linked to better survival outcomes. Notably, among the patients in our cohort, we observe substantial heterogeneity in the degree of clonal expansion and magnitude of T cell response. Our findings suggest that characterization of intra-tumoral T cell responses may enable selection of patients for immunotherapy, an approach that requires prospective validation in clinical trials.
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney A, Arnett A Nature. 2024; 637(8047):940-946.
PMID: 39604730 DOI: 10.1038/s41586-024-08261-8.
Cranioencephalic functional lymphoid units in glioblastoma.
Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Gruneboom A Nat Med. 2024; 30(10):2947-2956.
PMID: 39085419 PMC: 11485206. DOI: 10.1038/s41591-024-03152-x.
von Roemeling C, Patel J, Carpenter S, Yegorov O, Yang C, Bhatia A Nat Commun. 2024; 15(1):5871.
PMID: 38997283 PMC: 11245621. DOI: 10.1038/s41467-024-49989-1.
Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.
Pathania A Cancers (Basel). 2024; 16(12).
PMID: 38927907 PMC: 11201451. DOI: 10.3390/cancers16122201.